Drugs / AGTC-501
AGTC-501
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT07174726 | Sep 2025 → Dec 2029 expected | retinitis pigmentosa | Beacon Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06275620 | Nov 2023 → Nov 2025 overdue | retinitis pigmentosa | Beacon Therapeutics | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06333249 | Apr 2021 → Apr 2023 overdue | retinitis pigmentosa | Beacon Therapeutics | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT04850118 Comparator | Mar 2024 → Jun 2026 overdue | retinitis pigmentosa | Beacon Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGTC-501 | “The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to...” NCT07174726 ↗2“Each participant will receive the assigned dose of AGTC-501 in one eye on a single occasion.” NCT06333249 ↗ |
| Known as | laruparetigene zovaparvovec | “This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec ))...” NCT04850118 ↗1“The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to...” NCT07174726 ↗ |
| Known as | rAAV2tYF-GRK1-hRPGRco | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04850118 ↗ |
| Known as | rAAV2tYF-GRK1-RPGR | “A Phase 1/2 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized, Controlled, Masked, Multi-center...” NCT06333249 ↗1“AGTC-501 (rAAV2tYF-GRK1-RPGR)” NCT06275620 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “recombinant adeno-associated virus vector” NCT04850118 ↗ |
| Route | Other | “treated by subretinal injection” NCT07174726 ↗ |
| Target | RPGR | “Adeno-associated virus vector expressing a human RPGR gene” NCT04850118 ↗ |